Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: Results of a retrospective, multicentre, epidemiological cohort study in Germany

In Vivo

Volumn 25, Issue 6, 2011, Pages 983-990

  Vollbracht, Claudia ^a   Schneider, Berthold ^b   Leendert, Van ^d   Weiss, Gabriele ^a   Auerbach, Leo ^c   Beuth, Josef ^d  

^a Forschung und Entwicklung   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Ascorbic acid; Breast neoplasm; Depression; Fatigue; Intravenous vitamin C; Side effects; Surgery; Tumour pain

Indexed keywords

ANTINEOPLASTIC AGENT; ASCORBIC ACID; PASCORBIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AFTERCARE; ALTERNATIVE MEDICINE; ANOREXIA; ANTIOXIDANT ACTIVITY; ARTICLE; ASCORBIC ACID DEFICIENCY; BLEEDING TENDENCY; BREAST CANCER; CACHEXIA; CANCER ADJUVANT THERAPY; CANCER PAIN; CANCER PATIENT; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GERMANY; HEADACHE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); NAUSEA; OXIDATIVE STRESS; POSTOPERATIVE PERIOD; QUALITY OF LIFE; RETROSPECTIVE STUDY; RISK REDUCTION; SKIN TOXICITY; SLEEP DISORDER; TREATMENT OUTCOME;

EID: 80755125671     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Wyatt G, Sikorskii A, Wills CE and Su H: Complementary and alternative medicine use, spending, and quality of life in early stage breast cancer. Nurs Res 59(1): 58-66, 2010.
2. American Cancer Society: Guidelines for using complementary and alternative medicine. www.cancer.org, 2008.
3. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG and Gluud C: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev (2): CD007176, 2008.
4. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A and Blumberg JB: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 100(11): 773-783, 2008. (Pubitemid 351809666)
5. Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA and O'Connor OA: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 68(19): 8031-8038, 2008.
6. Espey MG, Chen Q and Levine M: Comment re: Vitamin C antagonizes the cytotoxic effects of chemotherapy. Cancer Res 69(22): 8830; author reply 8830-8831, 2009.
7. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a prodrug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102(38): 13604-13609, 2005. (Pubitemid 41420895)
8. Kim KN, Pie JE, Park JH, Park YH, Kim HW and Kim MK: Retinoic acid and ascorbic acid act synergistically in inhibiting human breast cancer cell proliferation. J Nutr Biochem 17(7): 454-462, 2006.
9. Hong SW, Jin DH, Hahm ES, Yim SH, Lim JS, Kim KI, Yang Y, Lee SS, Kang JS, Lee WJ, Lee WK and Lee MS: Ascorbate (vitamin C) induces cell death through the apoptosis-inducing factor in human breast cancer cells. Oncol Rep 18(4): 811-815, 2007.
10. Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 103(2): 183-189, 1996. (Pubitemid 26147697)
11. Fromberg A, Gutsch D, Schulze D, Vollbracht C, Weiss G, Czubayko F and Aigner A: Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol 67(5): 1157-1166, 2010.
12. El-Merzabani MM, El-Aaser AA, Osman AM, Ismael N and Abu el-Ela F: Potentiation of therapeutic effect of methanesulphonate and protection against its organ cytotoxicity by vitamin C in Ehrlich ascites carcinoma bearing mice. J Pharm Belg 44(2): 109-116, 1989. (Pubitemid 19139483)
13. Shimpo K, Nagatsu T, Yamada K, Sato T, Niimi H, Shamoto M, Takeuchi T, Umezawa H and Fujita K: Ascorbic acid and adriamycin toxicity. Am J Clin Nutr 54(6 Suppl): 1298S-1301S, 1991.
14. Prasad SB, Giri A and Arjun J: Use of subtherapeutical dose of cisplatin and vitamin C against murine Dalton's lymphoma. Pol J Pharmacol Pharm 44(4): 383-391, 1992. (Pubitemid 23009666)
15. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA and Levine M: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140(7): 533-537, 2004.
16. Casciari JJ, Riordan HD, Miranda-Massari JR and Gonzalez MJ: Effects of high dose ascorbate administration on L-10 tumor growth in guinea pigs. P R Health Sci J 24(2): 145-150, 2005.
17. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J and Levine M: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 105(32): 11105-11109, 2008.
18. Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH, Taghiyev AF, Du C, Knudson CM and Cullen JJ: Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res 16(2): 509-520, 2010.
19. Pollard HB, Levine MA, Eidelman O and Pollard M: Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo 24(3): 249-255, 2010.
20. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L and Miller WH Jr.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19(11): 1969-1974, 2008.
21. Drisko JA, Chapman J and Hunter VJ: The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. 0J Am Coll Nutr 22(2): 118-123, 2003.
22. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ and Levine M: Intravenously administered vitamin C as cancer therapy: three cases. Cmaj 174(7): 937-942, 2006.
23. Cameron E: Protocol for the use of vitamin C in the treatment of cancer. Med Hypotheses 36(3): 190-194, 1991.
24. Yeom CH, Jung GC and Song KJ: Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci 22(1): 7-11, 2007.
25. Kennedy DD, Tucker KL, Ladas ED, Rheingold SR, Blumberg J and Kelly KM: Low antioxidant vitamin intakes are associated with increases in adverse effects of chemotherapy in children with acute lymphoblastic leukemia. Am J Clin Nutr 79(6): 1029-36, 2004. (Pubitemid 41095955)
26. Wang C, Baumgartner RN, Yang D, Slattery ML, Murtaugh MA, Byers T, Hines LM, Giuliano AR and Baumgartner KB: No evidence of association between breast cancer risk and dietary carotenoids, retinols, vitamin C and tocopherols in Southwestern Hispanic and non-Hispanic White women. Breast Cancer Res Treat 114(1): 137-145, 2009.
27. Shah FD, Patel JB, Shukla SN, Shah PM and Patel PS: Evaluation of plasma non-enzymatic antioxidants in breast cancer etiology. Asian Pac J Cancer Prev 10(1): 91-96, 2009.
28. Singh P, Kapil U, Shukla NK, Deo S and Dwivedi SN: Association between breast cancer and vitamin C, vitamin E and selenium levels: results of a case-control study in India. Asian Pac J Cancer Prev 6(2): 177-180, 2005.
29. Schneider B: Analysis of therapeutic efficacy in observational cohort studies. Cancer Chemother Pharmacol 47: 35-37, 2001.
30. Beuth JH N, van Leendert R, Basten R, Noehle M and Schneider B: Safety and efficacy of local administration of Contractubex to hypertrophic scars in comparison to corticoid treatment. Results of a multicenter, comparative epidemiological cohort study in Germany. In Vivo 20: 277-284, 2006.
31. Borrelli E, Roux-Lombard P, Grau GE, Girardin E, Ricou B, Dayer J and Suter PM: Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med 24(3): 392-397, 1996. (Pubitemid 26097830)
32. Schorah CJ, Downing C, Piripitsi A, Gallivan L, Al-Hazaa AH, Sanderson MJ and Bodenham A: Total vitamin C, ascorbic acid, and dehydroascorbic acid concentrations in plasma of critically ill patients. Am J Clin Nutr 63(5): 760-765, 1996. (Pubitemid 26126597)
33. Nathens AB, Neff MJ, Jurkovich GJ, Klotz P, Farver K, Ruzinski JT, Radella F, Garcia I and Maier RV: Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg 236(6): 814-822, 2002. (Pubitemid 35403237)
34. Long CL, Maull KI, Krishnan RS, Laws HL, Geiger JW, Borghesi L, Franks W, Lawson TC and Sauberlich HE: Ascorbic acid dynamics in the seriously ill and injured. J Surg Res 109(2): 144-148, 2003. (Pubitemid 36315742)
35. Akinloye O, Adaramoye O and Kareem O: Changes in antioxidant status and lipid peroxidation in Nigerian patients with prostate carcinoma. Pol Arch Med Wewn 119(9): 526-532, 2009.
36. Esme H, Cemek M, Sezer M, Saglam H, Demir A, Melek H and Unlu M: High levels of oxidative stress in patients with advanced lung cancer. Respirology 13(1): 112-116, 2008.
37. Yalcin O, Karatas F, Erulas FA and Ozdemir E: The levels of glutathione peroxidase, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder. BJU Int 93(6): 863-866, 2004. (Pubitemid 38497044)
38. Mayland CR, Bennett MI and Allan K: Vitamin C deficiency in cancer patients. Palliat Med 19(1): 17-20, 2005. (Pubitemid 40202054)
39. Sakhi AK, Russnes KM, Thoresen M, Bastani NE, Karlsen A, Smeland S and Blomhoff R: Pre-radiotherapy plasma carotenoids and markers of oxidative stress are associated with survival in head and neck squamous cell carcinoma patients: a prospective study. BMC Cancer 9: 458, 2009.
40. Al-Gayyar MM, Eissa LA, Rabie AM and El-Gayar AM: Measurements of oxidative stress status and antioxidant activity in chronic leukaemia patients. J Pharm Pharmacol 59(3): 409-417, 2007. (Pubitemid 47050906)
41. Marcus SL, Petrylak DP, Dutcher JP, Paietta E, Ciobanu N, Strauman J, Wiernik PH, Hutner SH, Frank O and Baker H: Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells. Am J Clin Nutr 54(6 Suppl): 1292S-1297S, 1991.
42. Chevion S, Or R and Berry EM: The antioxidant status of patients subjected to total body irradiation. Biochem Mol Biol Int 47(6): 1019-1027, 1999. (Pubitemid 29308740)
43. Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E and Kirli S: Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 22(2): 67-73, 2007. (Pubitemid 46505714)
44. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A and Palasodkar R: Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 8(6): 365-370, 2003. (Pubitemid 38128544)
45. Chang CW, Chen MJ, Wang TE, Chang WH, Lin CC and Liu CY: Scurvy in a patient with depression. Dig Dis Sci 52(5): 1259-1261, 2007.
46. Binfare RW, Rosa AO, Lobato KR, Santos AR and Rodrigues AL: Ascorbic acid administration produces an antidepressant-like effect: evidence for the involvement of monoaminergic neurotransmission. Prog Neuropsychopharmacol Biol Psychiatry 33(3): 530-540, 2009.
47. Riordan HD, Riordan NH, Jackson JA, Casciari JJ, Hunninghake R, Gonzalez MJ, Mora EM, Miranda-Massari JR, Rosario N and Rivera A: Intravenous vitamin C as a chemotherapy agent: a report on clinical cases. P R Health Sci J 23(2): 115-118, 2004.
48. Drisko JA, Chapman J and Hunter VJ: The use of antioxidant therapies during chemotherapy. Gynecol Oncol 88(3): 434-439, 2003. (Pubitemid 36332002)
49. Abdel-Latif MM, Raouf AA, Sabra K, Kelleher D and Reynolds JV: Vitamin C enhances chemosensitization of esophageal cancer cells in vitro. J Chemother 17(5): 539-549, 2005. (Pubitemid 41695602)